ReShape Lifesciences Price To Sales vs. Price To Book
| RSLS Stock | USD 5.68 0.07 1.22% |
ReShape Lifesciences Price To Sales Ratio |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.42 | 0.6393 |
|
|
For ReShape Lifesciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ReShape Lifesciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ReShape Lifesciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ReShape Lifesciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ReShape Lifesciences over time as well as its relative position and ranking within its peers.
ReShape |
ReShape Lifesciences' Revenue Breakdown by Earning Segment
Check out Your Equity Center.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ReShape Lifesciences. If investors know ReShape will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ReShape Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 76.2 | Revenue Per Share 27.638 | Quarterly Revenue Growth (0.13) | Return On Assets (0.63) | Return On Equity (1.85) |
The market value of ReShape Lifesciences is measured differently than its book value, which is the value of ReShape that is recorded on the company's balance sheet. Investors also form their own opinion of ReShape Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is ReShape Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ReShape Lifesciences' market value can be influenced by many factors that don't directly affect ReShape Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ReShape Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ReShape Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ReShape Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ReShape Lifesciences Price To Book vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ReShape Lifesciences's current stock value. Our valuation model uses many indicators to compare ReShape Lifesciences value to that of its competitors to determine the firm's financial worth. ReShape Lifesciences is rated below average in price to sales category among its peers. It is rated fourth in price to book category among its peers fabricating about 5.22 of Price To Book per Price To Sales. At this time, ReShape Lifesciences' Price To Sales Ratio is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ReShape Lifesciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ReShape Price To Book vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
ReShape Lifesciences |
| = | 0.51 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
ReShape Lifesciences |
| = | 2.66 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
ReShape Price To Book Comparison
ReShape Lifesciences is currently under evaluation in price to book category among its peers.
ReShape Lifesciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ReShape Lifesciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ReShape Lifesciences will eventually generate negative long term returns. The profitability progress is the general direction of ReShape Lifesciences' change in net profit over the period of time. It can combine multiple indicators of ReShape Lifesciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -79.2 K | -83.2 K | |
| Operating Income | -14.6 M | -15.4 M | |
| Net Loss | -11.4 M | -12 M | |
| Income Tax Expense | 52 K | 49.4 K | |
| Income Before Tax | -11.3 M | -11.9 M | |
| Total Other Income Expense Net | 3.3 M | 3.5 M | |
| Net Loss | -26.2 M | -27.5 M | |
| Non Operating Income Net Other | -6.6 M | -6.2 M | |
| Net Loss | -41.6 M | -43.7 M | |
| Net Interest Income | -151 K | -158.6 K | |
| Interest Income | 959.40 | 911.43 | |
| Change To Netincome | 24.7 M | 18.2 M | |
| Net Loss | (110.88) | (116.42) | |
| Income Quality | 1.49 | 0.84 | |
| Net Income Per E B T | 1.00 | 0.87 |
ReShape Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ReShape Lifesciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ReShape Lifesciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ReShape Lifesciences' important profitability drivers and their relationship over time.
Use ReShape Lifesciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ReShape Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ReShape Lifesciences will appreciate offsetting losses from the drop in the long position's value.ReShape Lifesciences Pair Trading
ReShape Lifesciences Pair Trading Analysis
The ability to find closely correlated positions to ReShape Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ReShape Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ReShape Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ReShape Lifesciences to buy it.
The correlation of ReShape Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ReShape Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ReShape Lifesciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ReShape Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ReShape Lifesciences position
In addition to having ReShape Lifesciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Wholesale Thematic Idea Now
Wholesale
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Wholesale theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wholesale Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.